A Phase I-II Study to Evaluate the Efficacy and Safety of Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer After Failure to First-line Platinum-based Chemotherapy
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Cabozantinib (Primary) ; Niraparib (Primary)
- Indications Renal cell carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NICARAGUA
- 02 Feb 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 02 Feb 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 02 Feb 2019 Planned initiation date changed from 1 Sep 2018 to 1 Jun 2019.